Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 8/20 | 0.44 |
| ▸ | RBP4 | P02753 | 5/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 2/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315943 | 0.80 | HPGD (0.39) | HPGDNAMPTGRIA1 | |
| SCHEMBL3059830 | 0.78 | P2RY12 (0.59) | HPGDTTRRBP4P2RY12NAPEPLD | |
| SCHEMBL29521457 | 0.78 | P2RY12 (0.59) | HPGDTTRRBP4P2RY12NAPEPLD | |
| SCHEMBL316816 | 0.78 | P2RY12 (0.49) | HPGDTTRSCD5P2RY12 | |
| SCHEMBL316815 | 0.78 | P2RY12 (0.49) | HPGDTTRSCD5P2RY12 | |
| SCHEMBL2921143 | 0.78 | P2RY12 (0.59) | HPGDTTRRBP4P2RY12NAPEPLD | |
| SCHEMBL29521263 | 0.77 | P2RY12 (0.58) | HPGDTTRRBP4P2RY12NAPEPLD | |
| SCHEMBL3062229 | 0.75 | P2RY12 (0.50) | TTRRBP4P2RY12NAPEPLD | |
| SCHEMBL3062233 | 0.75 | P2RY12 (0.50) | TTRRBP4P2RY12NAPEPLD | |
| SCHEMBL18694038 | 0.74 | CFTR (0.58) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081903-B1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-05-07 | — | — | EP | disclosed |
| US-8093250-B2 | 2-aminocarbonyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-10 | — | — | US | disclosed |
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-11 | — | — | US | disclosed |
| EP-2081903-A2 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008044217-A2 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | P2RY12, P2RY2, P2RY1 | HPGD 1203/4885TTR 1956/4885RBP4 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.